Michael F. Cola's Insider Trades & SAST Disclosures
Michael F. Cola's most recent trade in Sage Therapeutics Inc was a trade of 12,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 10, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael F. Cola.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sage Therapeutics Inc | Michael F. Cola | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Michael F. Cola | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Michael F. Cola | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 10,500 | 29,298 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Michael F. Cola | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Michael F. Cola | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Michael F. Cola | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 9,000 | 18,798 (0%) | 0% | 0 | Common Stock | |
| Sage Therapeutics Inc | Michael F. Cola | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 9,947 | 9,947 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Michael F. Cola | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 78,116 | 78,116 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 51,740 | 51,740 | - | - | Stock Option (Right to Buy) | |
| Sage Therapeutics Inc | Michael F. Cola | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharmaceuticals Inc | Michael F. Cola | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 70,881 | 70,881 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 850,000 | 850,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 64,798 | 64,798 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2020 | 76,674 | 76,674 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 64,683 | 64,683 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Michael F. Cola | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2020 | 84,322 | 84,322 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Michael F. Cola | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.50 per share. | 09 Jun 2020 | 100,000 | 175,746 | - | 2.5 | 250,000 | Common Stock |
| Sage Therapeutics Inc | Michael F. Cola | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2020 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges